Cresco Labs Q3 EPS Boosted by Alliance Global Partners

Cresco Labs Inc. (OTCMKTS:CRLBF) has received a positive adjustment in its third-quarter earnings estimates from research analysts at Alliance Global Partners. In a report released on March 12, 2025, analyst A. Grey revised the expected earnings per share (EPS) for Q3 2025 to ($0.02), an improvement from the previous estimate of ($0.03). The current consensus for Cresco Labs' earnings for the full year is expected to be ($0.20) per share. Additionally, Alliance Global Partners provided expectations for Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS, and FY2026 earnings at ($0.08) EPS.

In a separate analysis, ATB Capital Markets downgraded Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on December 9, 2024. Presently, three analysts have assigned a hold rating to the stock, while one analyst has a buy rating and two analysts have given it a strong buy rating. According to data from MarketBeat, Cresco Labs holds an average rating of “Moderate Buy” along with an average price target of $3.00.

Cresco Labs Stock Performance

Cresco Labs’ stock opened at $0.73 on Monday, experiencing a minor decline of 0.8%. The company possesses a market capitalization of $358.29 million, a price-to-earnings (PE) ratio of -3.67, and a beta of 1.79. Its fifty-day moving average stands at $0.88, while its two-hundred-day moving average is $1.19. The stock has seen a 52-week low of $0.70 and a high of $2.60. Cresco Labs has a debt-to-equity ratio of 1.80, a quick ratio of 1.39, and a current ratio of 1.97.

The most recent quarterly earnings report was released on March 14, 2025, where the company announced earnings per share of ($0.01), aligning with the analysts’ expectations. Cresco Labs reported a negative net margin of 9.15% and a negative return on equity of 16.52%. The company generated revenue of $176.00 million for the quarter, which surpassed the consensus estimate of $172.10 million.

Overview of Cresco Labs

Cresco Labs Inc., along with its subsidiaries, is engaged in the cultivation, manufacturing, and retail sales of cannabis products, both for medical and recreational use in the United States. The company offers a variety of cannabis products under several brands. These include flowers, vape pens, live resins, and extracts sold under the Cresco brand, as well as vape carts and other marijuana products available under various other brands including High Supply, Good News, Wonder Wellness Co., and Remedi.

Cresco, Earnings, Stocks